Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Retained Earnings (2016 - 2025)

Cytokinetics (CYTK) has disclosed Retained Earnings for 16 consecutive years, with $630000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings changed N/A to $630000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $630000.0, a N/A change, with the full-year FY2025 number at $630000.0, changed N/A from a year prior.
  • Retained Earnings was $630000.0 for Q4 2025 at Cytokinetics, up from -$3.3 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $5.4 million in Q3 2024 to a low of -$3.3 billion in Q3 2025.
  • A 5-year average of -$781.6 million and a median of -$3.6 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 2228515.38% in 2022, then surged 716.36% in 2024.
  • Cytokinetics' Retained Earnings stood at -$1.2 billion in 2021, then crashed by 31.33% to -$1.6 billion in 2022, then crashed by 33.18% to -$2.1 billion in 2023, then surged by 100.26% to $5.4 million in 2024, then crashed by 88.31% to $630000.0 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Retained Earnings are $630000.0 (Q4 2025), -$3.3 billion (Q3 2025), and -$158000.0 (Q2 2025).